Some Psychiatric medication that has shown widespread use in Russia is unlicensed in Western countries. Some of these medications have RCTs showing benefit, eg. Afobazole showed increased anxiolytic properties when compared to diazepam and no withdrawal. Does this suggest that already existing compounds that patents aren’t owned by drug company will not achieve widespread use, how will physcedelics differ? How will physcedelics have RCTs (randomised controlled trials) conducted that compared to pre-existing treatments, look at long term efficacy and safety, and appropriate dose be funded that will help with approval by bodies such as NICE/FDA? The route of esketamine, (a form of Ketamine administered as a nasal spray patented by J&J for treatment resistant depression) seems to have significant drawbacks: high cost, no RCT compared to pre-existing treatments, how is this improved upon for physcedelics.
All I can say is, yes, these are concerns. Thankfully there has been plenty of research thus far on psilocybin, MDMA, and LSD, which are not patentable.
Some Psychiatric medication that has shown widespread use in Russia is unlicensed in Western countries. Some of these medications have RCTs showing benefit, eg. Afobazole showed increased anxiolytic properties when compared to diazepam and no withdrawal. Does this suggest that already existing compounds that patents aren’t owned by drug company will not achieve widespread use, how will physcedelics differ? How will physcedelics have RCTs (randomised controlled trials) conducted that compared to pre-existing treatments, look at long term efficacy and safety, and appropriate dose be funded that will help with approval by bodies such as NICE/FDA? The route of esketamine, (a form of Ketamine administered as a nasal spray patented by J&J for treatment resistant depression) seems to have significant drawbacks: high cost, no RCT compared to pre-existing treatments, how is this improved upon for physcedelics.
All I can say is, yes, these are concerns. Thankfully there has been plenty of research thus far on psilocybin, MDMA, and LSD, which are not patentable.